Bank of Nova Scotia
LXRX icon

Bank of Nova Scotia’s Lexicon Pharmaceuticals LXRX Stock Holding History

Bank of Nova Scotia’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$115K Buy
+73,707
New +$107K ﹤0.01% 1040

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bank of Nova Scotia's LXRX Position: Q1 2026 in Review

Bank of Nova Scotia opened a new position in Lexicon Pharmaceuticals (LXRX) in Q1 2026: 73,707 shares worth $115K. The stake represents ﹤0.01% of the portfolio and ranks #1040 among its holdings.

136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Bank of Nova Scotia held 73,707 shares of Lexicon Pharmaceuticals worth $115K as of Q1 2026.
  • Lexicon Pharmaceuticals was a new Bank of Nova Scotia position in Q1 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Bank of Nova Scotia's portfolio in Q1 2026, its #1040 holding.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Bank of Nova Scotia's 13F filing for Q1 2026, filed 14 May 2026.